01—Abstract
Summary
Summary of the 10-K filed February 21, 2025. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' FY2024 10-K shows a company still growing at a solid clip with strong profitability, though 2025 guidance points to a slower top line.
Revenue rose 6.5% reported (6.4% organic) to $3.90 billiona, driven mainly by price realization and recurring Companion Animal Group (CAG) diagnostics revenue, which made up about 80% of consolidated revenue. Gross margin expanded 120 basis points to 61.0%, and operating income grew 2.8% to $1.13 billion. Diluted EPS was $10.67, up from $10.06, and net income reached $887.9 million.
Results were held back by a $61.5 millionb charge tied to an ongoing royalty litigation matter, which the company has now accrued at $89.0 million. Cash generation remained strong, with operating cash flow of $929.0 million. Management returned capital aggressively: $837.0 million in buybacks in 2024, with roughly $1.5 billion of repurchases planned for 2025.
Cash fell to $288.3 millionc, and total debt is modest, with a gross debt to Adjusted EBITDA ratio of 0.65x and a net debt ratio of 0.44x, well inside the 3.5x covenant. Near-term maturities include a $250 million term loan due October 2025 and senior notes due in 2025 and 2026. Looking ahead, management expects U.S. same-store clinical visits to decline in 2025, reflecting sector capacity constraints and macroeconomic headwinds.
Foreign exchange is also a meaningful drag, with about $80 milliond of expected revenue impact and $0.21 of EPS headwind at current rates, partly offset by hedging. The effective tax rate is projected to rise to about 21.5%. Overall, investors are weighing durable recurring revenue and strong capital returns against softer visit trends and a stronger dollar.
02—Key points
Key Highlights
- Revenue grew 6.5% reported (6.4% organic) to $3.90B; CAG Diagnostics recurring revenue was $3.13B, about 80% of consolidated revenue.
- Gross margin improved 120 bps to 61.0%, and operating margin was 29.0% despite a $61.5M litigation-related G&A charge.
- Diluted EPS rose to $10.67 from $10.06; net income was $887.9M, up 5.1%.
- Operating cash flow was $929.0M; share repurchases totaled $837.0M in 2024, with about $1.5B planned for 2025.
- Leverage is low: gross debt to Adjusted EBITDA is 0.65x and net debt to Adjusted EBITDA is 0.44x, versus a 3.5x covenant.
- 2025 outlook flags a decline in U.S. same-store clinical visits and an estimated ~$80M revenue and ~$0.21 EPS FX headwind, with a projected tax rate of about 21.5%.
- Ongoing royalty litigation accrual was raised to $89.0M, and the company has about $211M of purchase obligations due in 2025.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, IDEXX Laboratories kept $0.23.
- Revenue$3.90B100.0%
- Cost of revenue−$1.52B39.0%
- Gross profit$2.38B61.0%
- Operating costs−$1.25B32.1%
- Operating income$1.13B29.0%
- Interest, other & tax−$240.5M6.2%
- Net income$887.9M22.8%
Where FY2024 revenue went
$3.90B- Cost of revenue: $1.52B, 39% of revenue
- Other operating costs: $1.03B, 26% of revenue
- Net income: $887.9M, 23% of revenue
- R&D: $219.8M, 5.6% of revenue
- Interest, other & tax: $240.5M, 6.2% of revenue
Kept 23% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 21, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $3.90B$3.66B | +6.5% |
| Cost of Revenue | $1.52B$1.47B | +3.2% |
| Gross Profit | $2.38B$2.19B | +8.6% |
| R&D Expenses | $219.79M$190.95M | +15.1% |
| Operating Expenses | $1.25B$1.09B | +14.4% |
| Operating Income | $1.13B$1.10B | +2.8% |
| Net Income | $887.87M$845.04M | +5.1% |
| EPS (Basic) | $10.77$10.17 | +5.9% |
| EPS (Diluted) | $10.67$10.06 | +6.1% |
| Shares Outstanding (Basic) | 82.47M83.07M | −0.7% |
| Shares Outstanding (Diluted) | 83.25M83.98M | −0.9% |
05—Questions
Frequently Asked Questions
What drove IDEXX's revenue growth in 2024?
Growth came mainly from higher realized prices and, to a lesser extent, volume. CAG Diagnostics recurring revenue rose 6.8% organically, led by IDEXX VetLab consumables (+10.0% organic) and reference laboratory services (+4.6%). Veterinary software and imaging revenue rose 7.3% organically, aided by an acquisition.
Why did G&A expense jump 31.7% in 2024?
The main driver was a $61.5 million expense for an ongoing litigation matter, which concerns alleged underpayment of royalties under an expired patent license agreement. The company has increased its accrual for that matter to $89.0 million. Higher IT, outside services, and acquisition costs also contributed.
How is IDEXX returning capital to shareholders, and can it sustain this pace?
IDEXX repurchased $837.0M of stock in 2024 and plans about $1.5B in 2025, funded largely by operating cash flow ($929M) and its credit facility. It has never paid a dividend. The company has 6.1 million shares remaining under its authorization. Sustaining this pace depends on operating cash flow and market conditions, and the company's cash balance fell to $288M.
What are the main near-term risks to IDEXX's outlook?
The key risks are softer U.S. clinical visit trends (same-store visits fell about 2% in 2024 and are expected to decline further), corporate consolidation and buying consortiums pressuring pricing, FX headwinds from a stronger U.S. dollar, and the royalty litigation outcome. Debt maturities of $250M in October 2025 and $167.8M in current debt also require refinancing or repayment.
06—Continue